Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17857763 | 0.92 | PDE3B (0.38) | MAOBMAOAPDE3BPDE3AKIF11 | |
| SCHEMBL15613479 | 0.87 | MAOA (0.41) | MAOBMAOAPDE3BPDE3AKIF11 | |
| SCHEMBL16844047 | 0.83 | PDE3B (0.43) | MAOBMAOAPDE3BPDE3AKIF11 | |
| SCHEMBL16844140 | 0.79 | PDE3B (0.43) | MAOBMAOAPDE3BPDE3AKIF11 | |
| SCHEMBL16841030 | 0.79 | RORC (0.43) | MAOBMAOAPDE3BPDE3AKIF11 | |
| SCHEMBL397141 | 0.78 | KIF11 (0.61) | PDE3BPDE3AKIF11RORCPTGS1 | |
| SCHEMBL27806612 | 0.78 | KIF11 (0.51) | PDE3BPDE3AKIF11RORCPTGS1 | |
| SCHEMBL16841034 | 0.77 | MAOB (0.53) | MAOBMAOAKIF11MMP3 | |
| SCHEMBL16844139 | 0.77 | PDE3B (0.42) | PDE3BPDE3AKIF11RORCNSD2 | |
| SCHEMBL15613721 | 0.76 | PDE3B (0.40) | MAOBMAOAPDE3BPDE3AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019179962-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
| EP-3218446-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2018-07-04 | — | — | EP | disclosed |
| US-9914876-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20180022996-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180022996-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20170369780-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| US-20170369784-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| WO-2017194665-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | WO | disclosed |
| US-20170002268-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160222293-A1 | MESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| WO-2016096082-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150210921-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150203756-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203755-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150175883-A1 | Bimesogenic Compounds and Mesogenic Media | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MTX1, NEFM, MTX2 | MAOB 535/4885MAOA 919/4885PDE3B 1993/4885 |
| US-20170369780-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MTX1, MTX2, MIF | MAOB 779/4885MAOA 1221/4885PDE3B 2678/4885 |
| US-20150210921-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885MAOA 4013/4885PDE3B 4695/4885 |
| US-20150175883-A1 | Bimesogenic Compounds and Mesogenic Media | SP1, FOXM1, S100A11 | MAOB 3274/4885MAOA 4013/4885PDE3B 4695/4885 |
| US-20150203756-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885MAOA 4013/4885PDE3B 4695/4885 |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3267/4885MAOA 3928/4885PDE3B 4686/4885 |
| US-20170369784-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MTX1, S100A11, MCRS1 | MAOB 2561/4885MAOA 3031/4885PDE3B 3957/4885 |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MTX1, S100A11, MCRS1 | MAOB 2561/4885MAOA 3031/4885PDE3B 3957/4885 |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885MAOA 4013/4885PDE3B 4695/4885 |
| US-20150203755-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885MAOA 4013/4885PDE3B 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.